Tag Archives: valeant pharmaceuticals

June, 2018

18 June
FDA Fails to Approve Valeant’s Plaque Psoriasis Treatment

LAVAL, Quebec, June 18, 2018 /PRNewswire/ — Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) …
Share

21 April
Valeant Prices Injectable Psoriasis Drug Siliq at $3,500 Per Month

LAVAL, Quebec, April 21, 2017 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), the company has decided to list SILIQ™ (brodalumab) injection, at $3,500 per month, which is the lowest injectable …
Share

2 November
Valeant Comments on Potential Sale of its Gastroenterology Business Unit

LAVAL, Quebec, Nov. 1, 2016 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) today issued the following statement regarding comments attributed to anonymous sources in a press report regarding its Gastroenterology business unit: “In accordance with its duties to shareholders and other stakeholders, management evaluates any …
Share

20 July
FDA Panel Recommends Approval of Valeant’s Psoriasis Drug

LAVAL, Quebec, July 19, 2016 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) has voted by a margin of 18 to 0 for the approval of brodalumab injection, 210 …
Share

16 March
Valeant Raises its Offer to Acquire Salix

After Endo International offered a rival bid, Valeant Pharmaceuticals International announced that it has raised its offer for gastrointestinal drugmaker Salix Pharmaceuticals. The companies announced that they have entered into an amendment to their agreement and plan merger. Valeant has increased its offer price to acquire all the outstanding common …
Share
11 March
Endo Threatens Valeant’s Deal with Competing Bid for Salix Pharmaceuticals

Today, Endo International plc confirmed that it has made a takeover bid for Salix Pharmaceuticals Ltd., looking to interrupt Valeant’s plans to acquire the gastrointestinal drugmaker. Endo said that it has submitted a proposal to the Board of Directors of Salix to acquire all of the outstanding shares of common …
Share

23 February
Valeant to Buy Salix Pharmaceuticals for $10.1 Billion

Valeant Pharmaceuticals International Inc. announced that it is buying Salix Pharmaceuticals Ltd. for $10.1 billion. Valeant is paying $158 a share for Salix, gaining a portfolio of gastrointestinal (GI) drugs and a strong near-term pipeline of innovative, new assets. The deal values Salix at about $14.5 billion including net debt …
Share